FREDUN PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of FREDUN PHARMACEUTICALS have increased by 0% YoY .
The Earnings Per Share (EPS) of FREDUN PHARMACEUTICALS has increased by 0 YoY. |
||
FREDUN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 539730]
| Consolidated | Mar2025 |
|---|---|
| Revenues | ₹0.00 Cr |
| Expenses | ₹0.00 Cr |
| Operating Profit (Excl OI) | ₹0.00 Cr |
| Other Income | ₹0.00 Cr |
| Interest | ₹0.00 Cr |
| Depreciation | ₹0.00 Cr |
| Profit Before Tax | ₹0.00 Cr |
| Profit After Tax | ₹0.00 Cr |
| Consolidated Net Profit | ₹0.00 Cr |
| Earnings Per Share (Rs) | ₹41.80 |
| PAT Margin (%) | 4.35 |
| ROE(%) | 13.96 |
| ROCE(%) | 16.16 |
| Total Debt/Equity(x) | 1.18 |
Key Financials |
||
| Market Cap | : | ₹ 1,300.8 Cr |
| Revenue (TTM) | : | ₹ 593.5 Cr |
| Net Profit(TTM) | : | ₹ 32.7 Cr |
| EPS (TTM) | : | ₹ 59.4 |
| P/E (TTM) | : | 39.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| FREDUN PHARMACEUTICALS | -2.5% | 28.2% | 251.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.2% | 12.5% | 10.6% |
| DIVIS LABORATORIES | 2.9% | 8.5% | 11.4% |
| TORRENT PHARMACEUTICALS | 0.3% | 5.7% | 36.3% |
| CIPLA | 10.4% | 15.9% | -5.8% |
| DR REDDYS LABORATORIES | 4.8% | 9% | 10.8% |
| MANKIND PHARMA | 5% | 18.6% | -1.7% |
| LUPIN | 0.3% | -3.2% | 10.2% |
| ZYDUS LIFESCIENCES | 6.5% | 5.5% | 12.2% |
FREDUN PHARMACEUTICALS Revenues
[BOM: 539730]
| Y-o-Y | 0 % |
| 5 Yr CAGR | 0 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.00 Cr | - | |
FREDUN PHARMACEUTICALS Operating Profit
[BOM: 539730]
| Y-o-Y | 0 |
| 5 Yr CAGR | 0 |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.00 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 0 |
| 5 Yr CAGR | 0 |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 0% | - | |
FREDUN PHARMACEUTICALS Profit After Tax
[BOM: 539730]
| Y-o-Y | 0 |
| 5 Yr CAGR | 0 |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹0.00 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 0 |
| 5 Yr CAGR | 0 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 4.35 % | - | |
FREDUN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 539730]
| Y-o-Y | 0 |
| 5 Yr CAGR | 0 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹42 | - | |
FREDUN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 539730]
| Y-o-Y | 0 |
| 5 Yr CAGR | 0 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 16.16% | - | |
FREDUN PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹2,365.0 |
| Current MarketCap | : | ₹ 1,300.8 Cr |
| Updated EOD on | : | May 19,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| FREDUN PHARMACEUTICALS | -2.5% |
28.2% |
251.1% |
| SENSEX | 0.9% |
-3.6% |
-7.3% |
FREDUN PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about FREDUN PHARMACEUTICALS Financials
How the annual revenues of FREDUN PHARMACEUTICALS have changed ?
The Revenues of FREDUN PHARMACEUTICALS have increased by 0% YoY .
How the Earnings per Share (EPS) of FREDUN PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of FREDUN PHARMACEUTICALS has increased by 0 YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs